glp-1 for obesity baton rouge Agonists: Revolutionizing the Treatment of Obesity, but Are They Enough? - Eric Velazquez, MD - Bariatric Surgeon - Longstreet Clinic Center Weight Management The GLP-1 Access Gap: Mapping

J Biol Chem 283:45434559 Chen C, Krausz KW, Shah YM, Idle JR, Gonzalez FJ (2009) Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity

Results of repeated measures linear mixed effect models indicated a significant interaction between group and time for BrAC ( 2 (7) = 16.36, p = 0.022, f = 0.36)

Effective inhibition of c-Met, p-AKT, and p-ERK was achieved by dual inhibition with the BRAF inhibitor (PLX4032) and c-Met inhibitor (PHA665752)

Gaining insight into these mechanisms can identify potential therapeutic targets to improve vascular health and manage cardiovascular diseases (Figure 1)